Mechanisms of cancer cell metastasis to the bone: a multistep process.

For metastasis to occur, tumor cells must first detach from their tissue of origin. This requires altering both the tissue of origin and the cancer cell. Once detached, cancer cells in circulation must also acquire survival mechanisms. Although many may successfully disseminate, variation exists in the efficiency with which circulating tumor cells home to and invade the bone marrow as metastastic seeds. Disseminated tumor cells that do successfully invade the marrow are secured by cell-cell and cell-extracellular matrix adhesion. However, establishing a foothold in the marrow is not sufficient for disseminated tumor cells to create metastases. A significant latent phase must be overcome by either rescuing cellular proliferation or attenuating micrometastatic mass dormancy programs. Finally, growing metastases fuel osteolysis, osteoblastogenesis and T-cell differentiation, creating a variety of tumor phenotypes. Each step in the metastatic cascade is rich in biological targets and mechanistic pathways.

[1]  James Ewing,et al.  Neoplastic Diseases: A Treatise on Tumours , 1928, The Indian Medical Gazette.

[2]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[3]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[4]  B. Zetter,et al.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis. , 1990, Biochimica et biophysica acta.

[5]  G. Miller,et al.  Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. , 1994, The Journal of urology.

[6]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[7]  Michael Kühl,et al.  Functional interaction of β-catenin with the transcription factor LEF-1 , 1996, Nature.

[8]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[9]  N. Maitland,et al.  Precise microdissection of human prostate cancers reveals genotypic heterogeneity. , 1998, Cancer research.

[10]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[11]  M. Pepper,et al.  Lymphangiogenesis and tumor metastasis: myth or reality? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Jian Zhang,et al.  Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro , 2001, The Prostate.

[13]  R. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[14]  Evan T Keller,et al.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. , 2002, Cancer research.

[15]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[16]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[17]  R. Salcedo,et al.  Role of Chemokines in Angiogenesis: CXCL12/SDF‐1 and CXCR4 Interaction, a Key Regulator of Endothelial Cell Responses , 2003, Microcirculation.

[18]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[19]  G. Roodman Mechanisms of bone metastasis. , 2004, Discovery medicine.

[20]  P. Codogno,et al.  Autophagy and signaling: their role in cell survival and cell death , 2005, Cell Death and Differentiation.

[21]  Christie M. Orschell,et al.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.

[22]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[23]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[24]  K. Pienta,et al.  The "emigration, migration, and immigration"of prostate cancer. , 2005, Clinical prostate cancer.

[25]  S. Chiba Concise Review: Notch Signaling in Stem Cell Systems , 2006 .

[26]  J. Aguirre-Ghiso,et al.  Tumor cell dormancy induced by p38SAPK and ER-stress signaling: An adaptive advantage for metastatic cells? , 2006, Cancer biology & therapy.

[27]  L. Akslen,et al.  Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.

[28]  P. Rameshwar,et al.  SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. , 2006, Blood.

[29]  Ralph S. Da Costa,et al.  Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. , 2007, Journal of the National Cancer Institute.

[30]  R. Vessella,et al.  Tumor cell dormancy: An NCI workshop report , 2007, Cancer biology & therapy.

[31]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[32]  H. Yamaguchi,et al.  Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. , 2007, Cancer research.

[33]  B. Trask,et al.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.

[34]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[35]  K. Pienta,et al.  Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer , 2008, Journal of cellular biochemistry.

[36]  K. Pienta,et al.  CCL2, survivin and autophagy: New links with implications in human cancer , 2008, Autophagy.

[37]  R. Vessella,et al.  Cancer micrometastasis and tumour dormancy   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[38]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[39]  K. Pienta,et al.  The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer* , 2008, Journal of Biological Chemistry.

[40]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[41]  D. Rodenhiser,et al.  Epigenetic contributions to cancer metastasis , 2008, Clinical and Experimental Metastasis.

[42]  C. Horak,et al.  The role of metastasis suppressor genes in metastatic dormancy   , 2008 .

[43]  L. Hartmann,et al.  Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor‐specific fluorescent ligands , 2008, International journal of cancer.

[44]  Bart Barlogie,et al.  Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. , 2008, Blood.

[45]  K. Pienta,et al.  Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts , 2009, Journal of cellular biochemistry.

[46]  W. Ellis,et al.  Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence , 2009, Clinical Cancer Research.

[47]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[48]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[49]  P. Carroll,et al.  Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy , 2009, Cancer.

[50]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[51]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[52]  Yuehua Wu,et al.  The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction , 2010, Cancer biology & therapy.

[53]  K. Pienta,et al.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. , 2011, The Journal of clinical investigation.

[54]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[55]  J. Schneider,et al.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. , 2011, Bone.

[56]  Yibin Kang,et al.  Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. , 2011, Cancer cell.

[57]  T. Fehm,et al.  Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis , 2011, Clinical Cancer Research.

[58]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[59]  Steven J. Greco,et al.  Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. , 2011, Cancer research.